A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients (TIGER)

  • End date
    Dec 31, 2022
  • participants needed
  • sponsor
    Shanghai Tong Ren Hospital
Updated on 23 April 2022
percutaneous coronary intervention
acute coronary syndrome


This study is to evaluate the safety and efficacy of 60mg ticagrelor plus 100mg Aspirin to prevent major adverse cardiovascular and cerebrovascular events in one years after drug-eluting stents implantation for Chinese ACS patients compared with 90mg ticagrelor plus 100mg Aspirin

Condition Acute Coronary Syndrome, Coronary Stent Implantation
Treatment Ticagrelor 60mg, Ticagrelor 90mg
Clinical Study IdentifierNCT04255602
SponsorShanghai Tong Ren Hospital
Last Modified on23 April 2022


Yes No Not Sure

Inclusion Criteria

Subject must be at least 18 years of age
Patients should have undergone successful percutaneous coronary intervention with drug-eluting stent for acute coronary syndrome
Subject understand the study requirements and the treatment procedures and provided informed consent before the procedure

Exclusion Criteria

Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study
Active bleeding
Known hypersensitivity or contraindication to study medications
Non-cardiac co-morbid conditions are present with life expectancy <2 year or that may result in protocol non-compliance (per site investigator's medical judgment)
Subjects with Cerebral hemorrhage history
Subjects with stroke history in half a year
subjects with malignant tumor
subjects with whom oral anticoagulants are needed
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note